The optimal timing for initiating G-CSF stimulation has been a topic of debate, owing to concerns regarding potential immunotoxicity (e.g., CRS and ICANS), compromised treatment response, and survival outcomes [80–82]. The gene discussed is CSF3; the disease is congenital rubella syndrome.